Ask about this productRelated genes to: SMYD2 Blocking Peptide
- Gene:
- SMYD2 NIH gene
- Name:
- SET and MYND domain containing 2
- Previous symbol:
- -
- Synonyms:
- HSKM-B, ZMYND14, KMT3C
- Chromosome:
- 1q32.3
- Locus Type:
- gene with protein product
- Date approved:
- 2003-04-28
- Date modifiied:
- 2014-11-19
Related products to: SMYD2 Blocking Peptide
Related articles to: SMYD2 Blocking Peptide
- Colorectal cancer (CRC) is the second most common cancer-causing death in the United States. The Mediterranean diet, rich in extra-virgin olive oil (EVOO), is associated with a lower risk of colorectal cancer (CRC). Earlier studies reported -(-)-oleocanthal (OC), the major EVOO phenolic, to be effective in CRC progression and recurrence suppression in a subcutaneous xenograft model by targeting the SMYD2-EZH2/c-MET signaling axis and favorably modulating gut microbiota (GM). However, lead validation in an orthotopically xenografted model that mimics the tumor microenvironment is yet to be achieved. The GM contribution to OC anti-CRC activity remains unknown. We used an orthotopic intra-cecally xenografted nude mouse model to validate OC anti--mutant CRC activity and assessed the contribution of OC GM modulation to this activity using an oral antibiotic depletion strategy. Daily oral 10 mg/kg OC impressively suppressed -mutant CRC HCT-116-Luc progression and metastasis more effectively than intraperitoneal administration 3×/week. By contrast, GM depletion with a broad-spectrum antibiotics cocktail (ABC) partially attenuated this activity, suggesting GM contribution to OC anti-CRC activity. Thus, fecal microbiota transplantation (FMT) was conducted using fresh daily oral fecal GM treatments collected from 20 mg/kg OC-dosed nude mouse donors. A week before FMT dosing, orthotopic HCT-116-Luc tumor-bearing recipient mice were subjected to GM depletion using daily oral ABC dosing. Recipient mice treated with FMT from OC-treated donors exhibited dramatic >99% reductions in primary and near-complete suppression of multi-organ metastatic tumor burden versus FMT controls. Collectively, oral OC is validated as an effective anti--mutant CRC lead. Future clinical trials can validate its anti-CRC potential in a human model. - Source: PubMed
Publication date: 2026/08/11
Tarun Md Towhidul IslamEbrahim Hassan YEl Sayed Khalid A - Breast cancer is a heterogeneous disease in which epigenetic dysregulation plays a critical role in tumor progression, therapeutic resistance, and cellular plasticity. Among epigenetic regulators, EZH2, the catalytic subunit of the polycomb repressor complex 2 (PRC2), has emerged as a key oncogenic driver through its role in H3K27 trimethylation (H3K27me3)-mediated transcriptional repression. This study aimed to evaluate the anti-tumor effects of the EZH2 inhibitor GSK343 and to investigate its impact on the expression of additional epigenetic regulators, SMYD2 and SMYD3, in breast cancer models. - Source: PubMed
Publication date: 2026/07/23
Silva Thaís Amanda DamascenoFernandes Eduardo VignotoBocchi MayaraNeto Fermino Sanches Lizartede Oliveira Fábio Morato - - Source: PubMed
Publication date: 2026/07/31
Chen XiupengKeeler Allison MWu Joae Qiong - Prostate cancer (PCa) is among the highest incidence malignancies in men, with high rates of inevitable resistance development, relapse, and mortality. Castration-resistant prostate cancer (CRPC) continued to pose substantial therapeutic challenges, highlighting the urgent need for effective treatment options. This study assessed the marine cembranoid sarcophine activity against the progression and recurrence of the metastatic CRPC (mCRPC) in mouse xenograft models. Protein and phosphorylation levels were assessed by immunoblotting and mRNA expression by qPCR and RNA sequencing. The in vivo efficacy was evaluated through tumor progression over 3 weeks followed by primary tumor excision and recurrence monitoring over an 8-week course. Sarcophine significantly reduced the mCRPC CWR-R1ca tumor volume by 74.1% and suppressed the epigenetic regulators EZH2 and SMYD2; lineage plasticity factors ASCL1 and BRN2; Wnt/stemness signaling markers β-catenin and LGR6; AKT total expression and activation; and invasion-associated proteins TRPC4 and MMP2 in primary tumors. Sarcophine effectively prevented the mCRPC locoregional recurrence, as well as lung and spleen distant recurrences, and effectively reduced recurrence in other organs. Transcriptomics-RNA-Seq analysis of primary tumors identified 2697 downregulated and 3534 upregulated genes, indicating broad transcriptional reprogramming following sarcophine treatments. These findings demonstrate coordinated suppression of multi-oncogenic pathways and validate the therapeutic potential of sarcophine to control mCRPC. - Source: PubMed
Publication date: 2026/06/23
Alhowiriny Abdullah TEbrahim Hassan YMudhish Ethar ADawud DalalEl Sayed Khalid A - Cervical cancer (CC) remains one of the most prevalent malignancies in the female reproductive system. Methionine metabolism (MM) plays a pivotal role in various biological processes and has been implicated in cancer progression. However, its mechanisms in CC remain unclear. - Source: PubMed
Publication date: 2026/07/21
Luo YongXie Xiao-HuiHuang Xiao-QinHu Hui-Quan